newsfilter
← Latest News
GlobeNewswire·

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results

Zumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway:- APEX Phase 2 Part A 52-week data expected this month- APEX Phase 2 Part B 16-week data expected